Special Issue

Regional Hyperthermia as Treatment of Solid Tumors

Message from the Guest Editors

Hyperthermia (HT) corresponds to the increase in temperature of several degrees in human or animal organ tissue with the goal of achieving an anti-tumoral effect. HT has multiple anti-cancer mechanisms, including the inhibition of DNA-damage repair, changes in perfusion, re-oxygenation with hypoxia reduction and anti-angiogenetic effects, the induction of heat-shock proteins, and immunological stimulation. In the last several decades, HT has been identified as the fourth pillar of anticancer treatment, alone or in combination with surgery, radiotherapy, and/or chemotherapy/immunotherapy. The HT technique works through different types of medical devices. With special reference to external loco-regional HT, this includes: capacitive HT, radiative HT, and hyperthermic intraperitoneal chemotherapy and hyperthermic isolated limb perfusion. In this Special Issue, we would like to focus attention on clinical outcomes deriving from HT alone and in combination with standard treatment regimens in several cancers, underlining biological anti-cancer mechanisms.

Guest Editors

Dr. Cosmo Damiano Gadaleta

Interventional and Medical Oncology, IRCCS Istituto Tumori Giovanni Paolo II, Bari, Italy

Dr. Girolamo Ranieri

Department of Interventional and Integrated Medical Oncology, National Cancer Research Centre, IRCCS Istituto Tumori "Giovanni Paolo II", Viale Orazio Flacco 65, 70124 Bari, Italy

Deadline for manuscript submissions

closed (31 December 2021)

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/si/69479

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/journal/cancers

MDPI

About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)